Vanda Pharmaceuticals Inc (NASDAQ:VNDA) shares, rose in value on Friday, July 11, with the stock price down by -5.01% to the previous day’s close as strong demand from buyers drove the stock to $4.74.
Actively observing the price movement in the last trading, the stock closed the session at $4.99, falling within a range of $4.74 and $5.0. The value of beta (5-year monthly) was 0.665. Referring to stock’s 52-week performance, its high was $6.36, and the low was $3.81. On the whole, VNDA has fluctuated by 1.72% over the past month.
With the market capitalization of Vanda Pharmaceuticals Inc currently standing at about $279.35 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-07.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VNDA’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of VNDA currently trading nearly 0.65% and 5.70% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.24, while the 7-day volatility ratio is showing 3.96% which for the 30-day chart, stands at 3.45%. Furthermore, Vanda Pharmaceuticals Inc (VNDA)’s beta value is 0.73.
A comparison of Vanda Pharmaceuticals Inc (VNDA) with its peers suggests the former has fared considerably weaker in the market. VNDA showed an intraday change of -5.01% in last session, and over the past year, it shrunk by -1.04%%.
Data on historical trading for Vanda Pharmaceuticals Inc (NASDAQ:VNDA) indicates that the trading volumes over the past 10 days have averaged 0.46 and over the past 3 months, they’ve averaged 462.40K. According to company’s latest data on outstanding shares, there are 58.93 million shares outstanding.
Nearly 6.87% of Vanda Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 77.37% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.73 million shares as on 2025-06-13, resulting in a short ratio of 10.6. According to the data, the short interest in Vanda Pharmaceuticals Inc (VNDA) stood at 832.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 4.87 million. The stock has fallen by -10.90% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VNDA stock heading into the next quarter.
